New Alzheimer's drug Leqembi offers hope to Oklahoma couple as they celebrate 50 years of marriage and fight against the ...

On December 10, TheFly reported that HSBC downgraded BIIB from Hold to Reduce, and lowered its price target to $143, citing ...

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid ...

Sentiment toward Biogen has been dampened by a combination of institutional activity and revised analyst outlooks. A major bank recently downgraded the stock to a "Reduce" rating, citing structural ...

Discover the facts about Leqembi, the new Alzheimer's drug, its IV administration, potential side effects, and its connection ...

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer's Patients Treated with Anti-Amyloid ...

Biogen (BIIB) has quietly outperformed the market over the past 3 months, with shares up about 20%. This performance has put the stock back on investor radars after a stretch of weaker multi year ...

Fresh questions over President Donald Trump's health and cognitive stamina have emerged after repeated reports of him ...